Utility and Work Productivity Data for Economic Evaluation of Breast Cancer Therapies in the Netherlands and Sweden
Authors:
- Nuz QuadriNQNuz Quadri
- Anke M. HövelsAHAnke M. Hövels
- Fleur T. van de WeteringFWFleur T. van de Wetering
- Hans TammingaHTHans Tamminga
- Jan H.M. SchellensJSJan H.M. Schellens
- Andrew J. LloydALAndrew J. Lloyd
- 1 April 2013
- journal article
- Published by Elsevier in Clinical Therapeutics
- Vol. 35 (4) , e1-e7
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Transferability of Model-Based Economic Evaluations: The Case of Trastuzumab for the Adjuvant Treatment of HER2-Positive Early Breast Cancer in the NetherlandsValue in Health, 2010
- Utilities of the EQ-5DPharmacoEconomics, 2009
- Productivity Costs of Cancer Mortality in the United States: 2000–2020JNCI: Journal of the National Cancer Institute, 2008
- Hot flashes, fatigue, treatment exposures and work productivity in breast cancer survivorsJournal of Cancer Survivorship, 2008
- Years of potential life lost and productivity costs because of cancer mortality and for specific cancer sites where human papillomavirus may be a risk factor for carcinogenesis-United States, 2003Cancer, 2008
- Health state utilities for metastatic breast cancerBritish Journal of Cancer, 2006
- A longitudinal study of health related quality of life and utility measures in patients with advanced breast cancerQuality of Life Research, 2001
- EuroQol: the current state of playHealth Policy, 1996
- The Validity and Reproducibility of a Work Productivity and Activity Impairment InstrumentPharmacoEconomics, 1993
- Issues in the Cross-National Assessment of Health TechnologyInternational Journal of Technology Assessment in Health Care, 1992